Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.
Also called NCT05266586
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 119 participants
- Sponsor
- Registry
-
NCT05266586
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05266586. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-09 (actual); primary completion 2022-08-12 (actual). Results posted on 2024-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
- Acronym
- ROSE2
- Condition
- Dyslipidemias
- Condition
- High Cholesterol
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Obicetrapib
- Intervention (Drug)
- Ezetimibe 10mg
- Intervention (Other)
- Obicetrapib placebo
- Intervention (Other)
- Ezetimibe placebo
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct05266586- Content hash
0a296a75131f8de4a2dc6212b6ff150207dcbf2a2e45a5c40e43d7d1b8f688d9